It is important in the context of drug discovery programs because IDO has a wide substrate specificity and has attracted considerable interest as a therapeutic target in neurological disease and cancer (12, –, 14), and there is commercial interest in the search for IDO inhibitors (with 1-Me-Trp already in clinical trials). The gene discussed is IDO1; the disease is nervous system disorder.